KALA BIO (KALA) vs NeuroSense Therapeutics (NRSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NeuroSense Therapeutics is the larger company by market cap ($7.2 million vs $5.5 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KALA | NRSN |
|---|---|---|
| Share price | $0.2863 | $3.80 |
| Market cap | $5.54M | $7.21M |
| 1-day change | -3.47% | +1.60% |
| EPS (TTM) | $-10.71 | $-47.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $95.50 | $26.64 |
| 52-week low | $0.286 | $3.56 |
| Distance from 52-week high | -99.70% | -85.74% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +2461.32% |
| Average volume | 1.46M | 21.29K |
| Shares outstanding | 19.34M | 1.90M |
| Employees | 6 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About KALA BIO
KALA stock →KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About NeuroSense Therapeutics
NRSN stock →NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
KALA vs NRSN FAQ
Which is bigger, KALA BIO or NeuroSense Therapeutics?
NeuroSense Therapeutics (NRSN) is larger, with a market capitalization of $7.21M compared with $5.54M for KALA BIO (KALA).
Are KALA BIO and NeuroSense Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.